---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-027925"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:48:18.604769+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%

## Summary
- GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).
- Cash, equivalents, investments $218.1M at Dec 31, 2023; runway into early 2026.
- R&D expenses Q4 2023: $41.8M (up from $25.2M Q4 2022) due to more active trials.
- ASPEN-06 interim: ORR 52% evorpacept combo vs 22% control; mDOR not reached vs 7.4 mo.
- Anticipated milestones: ASPEN-06 top-line all 122 subjects June-July 2024; Phase 3 start Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-027925
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/0000950170-24-027925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/alxo-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-027925
- JSON: https://secwatch.observer/filing/0000950170-24-027925.json
- Plain text: https://secwatch.observer/filing/0000950170-24-027925.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported the fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, EPS ($0.93) per basic and diluted share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share
  - EPS: ($0.93) per basic and diluted share
  - Result: reported results
  source text: On March 7, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024027925/0000950170-24-027925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.